Overcoming severe adverse reactions to venom immunotherapy using anti‐IgE antibodies in combination with a high maintenance dose
Clinical & Experimental Allergy2017Vol. 47(12), pp. 1631–1639
Citations Over TimeTop 10% of 2017 papers
E. Stretz, Eva Oppel, H.‐C. Räwer, R Châtelain, Sebastian Mastnik, Bernhard Przybilla, Franziska Ruëff
Abstract
Combining a temporary omalizumab therapy with an elevated maintenance dose seems a promising approach to achieve a tolerance of treatment in patients with a recurrent SAR to VIT.
Related Papers
- → Omalizumab anaphylaxis occurring outside the recommended observation times(2017)3 cited
- → Peanut Oral Immunotherapy and Omalizumab Treatment for Peanut Allergy(2012)7 cited
- → Are currently available biomarkers useful to discriminate CSU patients not controlled by low dose omalizumab maintenance therapy?(2020)4 cited
- → Novel dosing strategy of omalizumab during multi-allergen oral-immunotherapy(2020)1 cited
- → Clinical outcomes of patients with idiopathic anaphylaxis receiving omalizumab(2021)